Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation discusses concerns about importing Koshine KX, a hair loss treatment. A user reassures that there is no risk of getting caught.

The user plans to aggressively treat hair loss by using 1.25mg finasteride daily, 1mL minoxidil twice daily, and topical dutasteride with microneedling weekly, despite experiencing side effects from finasteride previously. They intend to switch to a maintenance routine with topical minoxidil and dutasteride after regaining hair.

A stem cell and adenosine triphosphate cocktail showed promising results in hair regrowth for male and female mice, with potential for future clinical trials. Users humorously reacted to the success in mice, expressing hope for human application.

Setipiprant, a PGD2 inhibitor, and RepliCel, a cell transplantation technology, are being explored as potential hair loss treatments. Current mainstream treatments like Minoxidil and Finasteride have limitations due to side effects and efficacy.

A treatment containing Wnt and Follistatin was found to be safe and effective for hair regrowth in a Phase 1 clinical trial. Specific treatments discussed include Minoxidil, Finasteride, and RU58841.

A 21-year-old shares their one-year progress using finasteride for hair loss, experiencing initial shedding but eventual regrowth, especially on the crown. They consider switching to dutasteride due to continued hair loss at the front temple and mid-scalp areas.

Nanoxidil may be more effective than Minoxidil for hair loss due to better follicle penetration, but it lacks widespread recognition and research because it's owned by a small company and classified as a cosmetic. The pharmaceutical system favors Minoxidil due to its established market presence and profitability, leaving Nanoxidil largely unstudied and unknown.

PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

A new treatment using dermal sheath cup cells may regrow hair and could require repeat treatments every 8 years. Users discuss ongoing trials and plan to use finasteride and minoxidil until the treatment is available.

The conversation discusses a hair loss treatment involving oral minoxidil, topical finasteride, and a custom topical formulation with minoxidil, cetirizine, finasteride, progesterone, and hydrocortisone. The user seeks advice on the effectiveness of these ingredients for diffuse thinning.

The conversation discusses the anticipation of clascoterone scalp treatment results for hair loss, with concerns about its availability and high cost. Users express hope for positive outcomes and affordable access.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

People are discussing JXL-069 (PP405) for hair loss, with some experimenting with a 0.05% topical gel. Concerns about safety and efficacy persist due to limited testing and lack of official approval.

A user shared progress pictures 1.5 months after a hair transplant of 3500 grafts, using oral finasteride, topical finasteride, minoxidil, and vitamins. They are concerned about potential shock loss and the thinning appearance.

Two Chinese suppliers provided legitimate RU58841, confirmed through a free drug testing service. The vendors were Shaanxi Greenyo Biotech and Lyphar, found on Made-in-China.

Several new hair loss treatments are in development, with Cosmo Breezula and Kintor KX826 being the furthest along, expected to be commercialized by 2027. Veradermics is the only treatment in pill form, while others like KX/GT/Breezula will be topical.

Stem cell-related treatments and drugs like RCGD423 and WAY are being tested for hair growth. Clinics are conducting tests on patients who haven't had previous treatments.

The conversation discusses hair loss treatments, specifically using Minoxidil, microneedling, and finasteride. The user is concerned about worsening hair loss and is advised to consider finasteride.

Nizoral 1% shampoo can be used continuously for hair loss, but it may cause dryness, which can be managed with conditioners. Some users combine it with other treatments like minoxidil and AHK-Cu for better results.

The user experienced chest pain and increased heart rate after microneedling while using topical minoxidil for hair loss. They are unsure if minoxidil is effective without microneedling.

Adding non-prescription topicals like alfatradiol and Zix to a standard fin/min/niz regimen may help with scalp inflammation and shedding, but their long-term effectiveness varies. Zix is recommended for reducing scalp inflammation and enhancing the effectiveness of other treatments.

The conversation discusses interest in peptides for hair loss, specifically mentioning ahkCU and ghkCU. A user is considering adding ghkCU to their treatment regimen.

Copper peptides are being discussed for hair loss treatment, with users reporting positive results using topical applications. There is interest in sourcing, application methods, and potential side effects.

The conversation is about a user considering joining a clinical study for Clascoterone (Breezula) after experiencing no results with topical finasteride and minoxidil, and side effects from oral finasteride. The user is seeking advice on clinical study participation and experiences.

Clascoterone showed promising initial results for hair regrowth but failed to replicate them, leading to disappointment. Users discuss combining it with minoxidil and other treatments, noting its current availability only in lower concentrations.

The user improved their hair loss from a Norwood scale 2.5/3 to 1.5/2 using treatments including 2.5 mg dutasteride, RU58841, 15 mg oral minoxidil, isoflavones, NAC, pumpkin seed oil, NAD+, and Vipelin, but still experiences temple recession. Other users expressed concern over the high dosages of oral minoxidil and dutasteride.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

Clascoterone is nearing regulatory submission as a potential new treatment for androgenetic alopecia, with positive Phase III results, while discussions continue about other treatments like PP405, minoxidil, and finasteride. Some users express excitement for clascoterone and Breezula, despite concerns about the effectiveness and practicality of topical treatments.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.